1
|
Hauser B, Sangesland M, Lam EC, St Denis KJ, Sheehan ML, Vu ML, Cheng AH, Sordilla S, Lamson DT, Almawi AW, Balazs AB, Lingwood D, Schmidt AG. Heterologous Sarbecovirus Receptor Binding Domains as Scaffolds for SARS-CoV-2 Receptor Binding Motif Presentation. ACS Infect Dis 2024; 10:553-561. [PMID: 38281136 PMCID: PMC10862550 DOI: 10.1021/acsinfecdis.3c00483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Revised: 01/04/2024] [Accepted: 01/04/2024] [Indexed: 01/30/2024]
Abstract
Structure-guided rational immunogen design can generate optimized immunogens that elicit a desired humoral response. Design strategies often center on targeting conserved sites on viral glycoproteins that will ultimately confer potent neutralization. For SARS-CoV-2 (SARS-2), the surface-exposed spike glycoprotein includes a broadly conserved portion, the receptor binding motif (RBM), that is required to engage the host cellular receptor, ACE2. Expanding humoral responses to this site may result in a more potent neutralizing antibody response against diverse sarbecoviruses. Here, we used a "resurfacing" approach and iterative design cycles to graft the SARS-2 RBM onto heterologous sarbecovirus scaffolds. The scaffolds were selected to vary the antigenic distance relative to SARS-2 to potentially focus responses to RBM. Multimerized versions of these immunogens elicited broad neutralization against sarbecoviruses in the context of preexisting SARS-2 immunity. These validated engineering approaches can help inform future immunogen design efforts for sarbecoviruses and are generally applicable to other viruses.
Collapse
Affiliation(s)
- Blake
M. Hauser
- Ragon
Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States
| | - Maya Sangesland
- Ragon
Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States
| | - Evan C. Lam
- Ragon
Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States
| | - Kerri J. St Denis
- Ragon
Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States
| | - Maegan L. Sheehan
- Ragon
Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States
| | - Mya L. Vu
- Ragon
Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States
| | - Agnes H. Cheng
- Ragon
Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States
| | - Sophia Sordilla
- Ragon
Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States
| | - Dana Thornlow Lamson
- Ragon
Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States
- Department
of Microbiology, Harvard Medical School, Boston, Massachusetts 02115, United States
| | - Ahmad W. Almawi
- Center
for Molecular Interactions, Department of Biological Chemistry and
Molecular Pharmacology, Harvard Medical
School, Boston, Massachusetts 02115, United States
| | - Alejandro B. Balazs
- Ragon
Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States
| | - Daniel Lingwood
- Ragon
Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States
| | - Aaron G. Schmidt
- Ragon
Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts 02139, United States
- Department
of Microbiology, Harvard Medical School, Boston, Massachusetts 02115, United States
| |
Collapse
|